JTJames R. Treat

James R. Treat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James R. Treat has a total of 219 co-authors. Here are the top co-authors by number of shared publications:

  • Adam Ian Rubin

    New York University Grossman School of Medicine New York New York USA

    5 shared publications
  • Leslie Castelo-Soccio

    Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland

    5 shared publications
  • Adam I. Rubin

    Section of Dermatology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    4 shared publications
  • Albert C. Yan

    Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    4 shared publications
  • Michelle Oboite

    Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA

    4 shared publications
  • Marissa J. Perman

    Section of Dermatology, Department of Pediatrics The Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

    3 shared publications

Latest Publications

  • Open Access

    Phase 2 study of the safety and efficacy of QTORIN rapamycin in the treatment of microcystic lymphatic malformations

    by James Treat, Jeffrey Martini, Jason T. Connor, Alison Small, Tracy Funk, Milton Waner, Joyce Teng

    Objectives: The objective of this Phase 2 study was to determine the safety and efficacy of QTORIN rapamycin 3.9% anhydrous gel for the treatment of cutaneous microcystic lymphatic malformations (LM). Design: The study was a multicenter, baseline-controlled Phase 2 clinical trial. Setting: The study was performed at 5 clinical sites in the United States. Participants: Participants were ≥6 years old with a clinical diagnosis of cutaneous microcystic LM. Intervention: Participants self-administered topical QTORIN rapamycin once daily for 12 weeks. Main Outcome Measurements: Outcomes were measured via standardized clinician- and patient-reported outcomes, including clinician global impression of change, clinician global impression of severity (CGI-S), patient global impression of severity, patient global impression of change (PGI-C), as well as lesion leaking or bleeding, thickness/height/size of lesion, LM symptom severity scale, dermatology life quality index, and overall patient satisfaction. Results: Safety, clinical examinations, laboratory evaluations, and quantification of sirolimus blood levels, suggested that QTORIN rapamycin was generally safe and well-tolerated. Efficacy indicated statistically significant improvements in endpoints with treatment. Clinician and patient reports were supported by visual photographs showing significant improvement in lesions over the course of treatment. Conclusions: This Phase 2 study provides compelling evidence of the safety and efficacy of QTORIN rapamycin, a novel 3.9% topical sirolimus formulation, for the treatment of microcystic LM and supports further development including a larger trial in this patient population.


  • Widespread keratinocytic epidermal nevus with an associated chylous pericardial effusion

    by Georgina Rowe, Kristen M. Snyder, James R. Treat

    A 17-year-old male presented for review of a widespread keratinocytic epidermal nevus (KEN) in the setting of a chronic pericardial effusion. Biopsy of the epidermal nevus revealed a KRAS mutation. Pericardiocentesis revealed a chylous effusion and magnetic resonance lymphangiogram demonstrated an underlying lymphatic malformation. There are rare case reports of KEN with an associated KRAS mutation. This case highlights the importance of being alert to epidermal nevus syndrome, particularly in patients with a widespread nevus and seemingly unrelated pathology.


  • Top Cited Papers
    Open Access

    Human germline heterozygous gain-of-functionSTAT6variants cause severe allergic disease

    by Mehul Sharma, Daniel Leung, Mana Momenilandi, Lauren C.W. Jones, Lucia Pacillo, Alyssa E. James, Jill R. Murrell, Selket Delafontaine, Jesmeen Maimaris, Maryam Vaseghi-Shanjani, et al.

    STAT6 (signal transducer and activator of transcription 6) is a transcription factor that plays a central role in the pathophysiology of allergic inflammation. We have identified 16 patients from 10 families spanning three continents with a profound phenotype of early-life onset allergic immune dysregulation, widespread treatment-resistant atopic dermatitis, hypereosinophilia with esosinophilic gastrointestinal disease, asthma, elevated serum IgE, IgE-mediated food allergies, and anaphylaxis. The cases were either sporadic (seven kindreds) or followed an autosomal dominant inheritance pattern (three kindreds). All patients carried monoallelic rare variants in STAT6 and functional studies established their gain-of-function (GOF) phenotype with sustained STAT6 phosphorylation, increased STAT6 target gene expression, and TH2 skewing. Precision treatment with the anti–IL-4Rα antibody, dupilumab, was highly effective improving both clinical manifestations and immunological biomarkers. This study identifies heterozygous GOF variants in STAT6 as a novel autosomal dominant allergic disorder. We anticipate that our discovery of multiple kindreds with germline STAT6 GOF variants will facilitate the recognition of more affected individuals and the full definition of this new primary atopic disorder.


  • Safety of dupilumab in a 5‐month‐old infant with severe atopic dermatitis

    by Sonia A. Havele, Michele C. Khurana, Patrick McMahon, Aditi S. Murthy, Marissa J. Perman, James R. Treat

    Dupilumab is a fully humanized monoclonal antibody that suppresses Th2‐mediated inflammation by inhibiting signaling of interleukin‐4 and interleukin‐13 through the interleukin‐4 alpha receptor subunit, and is approved by the FDA for the treatment of moderate to severe atopic dermatitis (AD) in children 6 years of age and older. While initial data from phase 2 trials in children less than 6 years are promising, dupilumab use in children less than 6 months of age is not well studied. Here we present a case of a 5‐month‐old boy with severe primary AD, eosinophilia, hypogammaglobulinemia, and poor weight gain, who was successfully treated with dupilumab and experienced no serious adverse effects. To our knowledge, this is the youngest patient to receive dupilumab to date.


  • Cutaneous mastocytosis in a child with a de novo GNB1 mutation

    by Katherine Lattanzio, Mary Larijani, James R. Treat

    In the last few years, de novo mutations in the GNB1 gene have been found to cause a neurodevelopmental disorder typically characterized by global developmental delay and hypotonia. Only 4 cases of maculopapular cutaneous mastocytosis in children with GNB1 mutations have been reported to date. Here, we describe another case of the condition with concomitant cutaneous mastocytosis.


  • Misdiagnosis of capillary malformations in darker skin phototypes

    by Bede N. Nriagu, Victoria R. Sanders, Lionel Bercovitch, Kristen Snyder, Elizabeth A. Cross, James R. Treat, Sarah E. Sheppard

    In the dermatologic medical literature, there is an underrepresentation of conditions in individuals of color. Due to the lack of representation, it may be harder for clinicians to recognize certain diagnoses in patients with darker skin phototypes leading to misdiagnosis and affecting overall patient management, outcomes, and satisfaction. Here, we present four Black or Indigenous People of Color who were initially referred for hyperpigmentation, hemihyperplasia, or café au lait spots and found to have syndromic capillary malformations.


  • A case of disseminated Lyme disease in a child with skin of color

    by Christina E. Bax, Ashley K. Clark, Michelle Oboite, James R. Treat

    Disseminated Lyme disease requires treatment to prevent severe sequelae, particularly neurologic. We report here a case of disseminated Lyme disease in a patient with skin of color. Pediatric dermatologists must maintain a high clinical suspicion for Lyme disease and be aware of how typical cutaneous findings may appear differently in skin of color.


  • Lichen striatus colocalized with a Spitz nevus

    by Corinne Rauck, Cameron Gudobba, James R. Treat, Adam I. Rubin

    A 7-year-old healthy girl presented with an 11-month history of an asymptomatic red, dome-shaped papule on her right medial elbow and 6-month history of linearly distributed, few millimeter, flesh-colored papules extending from and including the red papule. Histopathology demonstrated features of both a Spitz nevus and lichen striatus. The Spitz nevus was removed with a punch biopsy and the lichen striatus subsequently resolved. To our knowledge, co-localization of a Spitz nevus with lichen striatus has not been previously reported and highlights the potential association between the immunogenicity of Spitz nevi and the development of lichen striatus.


  • Neuroaxial Infantile Hemangiomas: Imaging Manifestations and Association with Hemangioma Syndromes

    by T. Feygin, A.E. Goldman-Yassen, D.J. Licht, J.E. Schmitt, A. Mian, A. Vossough, L. Castelo-Soccio, J.R. Treat, A. Bhatia, A.N. Pollock

    BACKGROUND AND PURPOSE: Infantile hemangiomas are common lesions in the pediatric population; in rare cases, an infantile hemangioma can be detected along the neural axis. The purposes of our study included determination of the incidence, location, and imaging appearance of neuroaxial infantile hemangiomas and their syndromic association. We also assessed additional features of cerebral and cardiovascular anomalies that may be associated with neuroaxial lesions. MATERIALS AND METHODS: A retrospective cohort study was performed, searching the radiology database for patients with segmental infantile hemangiomas referred for assessment of possible hemangioma syndromes. We retrospectively reviewed brain and spine MR imaging studies, with particular attention paid to neuroaxial vascular lesions, as well as the relevant clinical data. Neuroaxial hemangioma imaging findings were described, and comparison of segmental cutaneous infantile hemangioma location with the imaging findings was performed in patients with confirmed hemangioma syndromes and in patients with isolated skin infantile hemangioma. RESULTS: Ninety-five patients with segmental infantile hemangioma were included in the study, 42 of whom had a hemangioma syndrome; of those, 41 had posterior fossa brain malformations, hemangioma, arterial lesions, cardiac abnormalities, and eye abnormalities (PHACE) syndrome and 1 had diffuse neonatal hemangiomatosis. Neuroaxial involvement was detected in 20/42 patients (48%) with hemangioma syndromes and in no subjects with isolated segmental infantile hemangioma (P < .001). The most common intracranial hemangioma location was within the ipsilateral internal auditory canal (83%). CONCLUSIONS: Many pediatric patients with segmental infantile hemangioma in the setting of hemangioma syndromes, especially those with PHACE, had neuroaxial hemangiomas. This finding may potentially lead to requiring additional clinical evaluation and management of these patients.